866-997-4948(US-Canada Toll Free)

Uterine Cancer Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Oct 2012

Category :

Cancer

No. of Pages : 51 Pages


Uterine Cancer Pipeline Review, H2 2012

Global Markets Directs, 'Uterine Cancer Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Uterine Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uterine Cancer. Uterine Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Uterine Cancer.
  • A review of the Uterine Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Uterine Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Uterine Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Uterine Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Uterine Cancer Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Uterine Cancer 8
Uterine Cancer Therapeutics under Development by Companies 10
Uterine Cancer Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Uterine Cancer Therapeutics Products under Development by Companies 18
Uterine Cancer Therapeutics Products under Investigation by Universities/Institutes 19
Companies Involved in Uterine Cancer Therapeutics Development 21
Sanofi-Aventis 21
Azaya Therapeutics, Inc. 22
EndoCeutics, Inc. 23
Aragon Pharmaceuticals, Inc. 24
Eurofarma 25
Uterine Cancer Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
Pegfilgrastim + Docetaxel + Gemcitabine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 33
Bevacizumab + Filgrastim + Docetaxel + Gemcitabine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 35
Gemcitabine + Docetaxel + Filgrastim + Pegfilgrastim - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Ifosfamide + Paclitaxel - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Gemcitabine + Cisplatin - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Acolbifene - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Uterine Cancer Therapeutics Drug Profile Updates 43
Uterine Cancer Therapeutics Discontinued Products 44
Uterine Cancer Therapeutics - Dormant Products 45
Uterine Cancer Product Development Milestones 47
Featured News & Press Releases 47
Jun 13, 2012: Azaya Therapeutics Reports Phase I Clinical Trial Results Of ATI-1123 47
May 29, 2012: Immunovaccine To Present Clinical Data On DPX-0907 Cancer Vaccine At 2012 ASCO Annual Meeting 48
May 28, 2008: BiPar Sciences Expands Clinical Development Of BSI-201, A Novel PARP Inhibitor, With Phase II Trial In Uterine Cancer 48

Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Table


Number of Products Under Development for Uterine Cancer, H2 2012 8
Products under Development for Uterine Cancer Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Sanofi-Aventis, H2 2012 21
Azaya Therapeutics, Inc., H2 2012 22
EndoCeutics, Inc., H2 2012 23
Aragon Pharmaceuticals, Inc., H2 2012 24
Eurofarma, H2 2012 25
Assessment by Monotherapy Products, H2 2012 26
Assessment by Combination Products, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 31
Uterine Cancer Therapeutics Drug Profile Updates 43
Uterine Cancer Therapeutics Discontinued Products 44
Uterine Cancer Therapeutics Dormant Products 45

List of Chart


Number of Products under Development for Uterine Cancer, H2 2012 8
Products under Development for Uterine Cancer Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Discovery and Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 26
Assessment by Combination Products, H2 2012 27
Assessment by Route of Administration, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Molecule Type, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 31

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *